Agios Pharmaceuticals, Inc.(AGIO)

Description: Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.

---

Keywords: Cancer Biopharmaceutical Acid Hydrogen Organic Chemistry Metabolism Glutamate Inborn Errors Of Metabolism Agios Pharmaceuticals Glutaminase Glutamine Glutaric Aciduria Type 1 Idh1 Pyruvate Kinase Deficiency

---

Home Page: www.agios.com

AGIO Technical Analysis

88 Sidney Street
Cambridge, MA 02139-4169
United States
Phone: 617 649 8600

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)